Fisher Scientific International Inc

Fisher Scientific International — Merger or Acquisition (August 2004)

26 slides from Fisher Scientific International's merger presentation, Aug 9, 2004

  1. Slide 1: The World Leader in Serving Science

    August 9, 2004 The World Leader in Serving Science

  2. Slide 2: Safe Harbor and Regulation G Statement

    This presentation contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on Fisher's and Apogent's current expectations and beliefs and are subject to a number of risks, uncertainties and a

  3. Slide 3: Investment Highlights

    Investment Highlights Favorable market dynamics Powerful channel position Proven track record Significant upside opportunities Strong earnings and cash flow growth

  4. Slide 4: A market leader

    2004 Pro forma - $5.3 Billion* Scientific Research 0.74 Clinical Lab 0.23 BioPharma Production 0.03 Fisher Scientific - Revenues by Market * Pro forma for Apogent transaction A market leader

  5. Slide 5: Favorable Market Dynamics - Scientific Research

    Favorable Market Dynamics - Scientific Research Global market - $20 Billion R&D spending growth Pressure on drug development costs Consolidation Long-term growth rate: 5 - 8% Sources: Laboratory Products Association, SDI Inc., SAI, and management estimates. Scientific Research 0.74 Clinical Lab 0.23

  6. Slide 6: Scientific Research Market

    Customers: Pharma / biotech Universities / medical research Food and agriculture Industrial Government Products and Services: Lab consumable supplies Reagents / biochemicals Lab workstations and equipment Pharma services Broad portfolio of products and services Scientific Research Market

  7. Slide 7: Favorable Market Dynamics - Biopharma Production

    Global market* - $5+ billion Increased number of biotech drugs Concern about contamination Long-term growth rate: 15 - 25% *Includes: bioreactors, containers, serum and media, process liquids, chromatography and filtration products and other supplies. Sources: Global Industry Analysts (GIA),Thomas W

  8. Slide 8: Favorable Market Dynamics - Clinical Lab

    Favorable Market Dynamics - Clinical Lab U.S. market - $10 billion Aging population Growth of specialized testing Long-term growth rate: 4 - 5% Sources: Freedonia Group and management estimates. Scientific Research 0.74 Clinical Lab 0.23 BioPharma Production 0.03 Clinical Lab 23%

  9. Slide 9: Clinical Lab Market

    Customers: Hospitals Reference labs Physician office labs Products and Services: Lab consumable supplies Rapid test kits Microbiology products Instruments Clinical lab specialist Clinical Lab Market

  10. Slide 10: Fisher's Competitive Advantage

    Broad product and service offering Globally integrated supply chain Extensive sales and marketing footprint Proven acquisition capabilities Fisher's Competitive Advantage Critical elements of success

  11. Slide 11: Broad Product and Service Offering

    Broad Product and Service Offering Competitive Advantage * Pro forma for the Apogent transaction. 80% consumable One-stop shop Customer/product diversification Comprehensive proprietary portfolio 2001 2002 2003 2004PF* East 1.1 1.3 1.6 3.2 Proprietary Product Sales ($ in billions) 2001 2002 2003 200

  12. Slide 12: Globally Integrated Supply Chain

    Competitive Advantage Effective supply chain solutions Enhanced capabilities for global customers Global sourcing capability State-of-the-art systems Globally Integrated Supply Chain

  13. Slide 13: Extensive Global Sales and Marketing Footprint

    Extensive Global Sales and Marketing Footprint Technical support Supply chain solutions 1,200 customer service reps 1,500 sales generalists 800 technical specialists Competitive Advantage Unmatched sales and marketing footprint

  14. Slide 14: Strong Acquisition Track Record

    Strong Acquisition Track Record Enhanced market position Competitive Advantage Product companies (19 acquisitions) Domestic International Distribution companies (18 acquisitions) Domestic International

  15. Slide 15: Powerful Channel Position

    Powerful Channel Position Serving 350,000 customers in 145 countries 6,000 suppliers Scientific research customers Clinical lab customers Fisher brand products

  16. Slide 16: Strong Platform for Future Growth

    Sales and marketing New product development Strong Platform for Future Growth Pursue Strategic Acquisitions Acquisition-related synergies Enhance product mix Earnings growth Working capital Capital expenditures Life science Pharma services Other consolidation opportunities Increase Cash Flow Enhance

  17. Slide 17: Leverage Sales and Marketing Footprint

    Leverage Sales and Marketing Footprint Sales generalists Accelerate Revenue Growth Current State Future State Technical specialists Customer service reps Application specialists Technical support Supply chain solutions Sales generalists Customer service reps Technical specialists

  18. Slide 18: Accelerate Revenue Growth: New Product Development

    Accelerate Revenue Growth New Product Development Serum free media Disposable bioprocess containers Oligos for antisense drugs RNAi Pathway probes

  19. Slide 19: Enhance Margins: Apogent Merger Synergies

    Enhance Margins Apogent Merger Synergies Rationalize manufacturing operations $50 Consolidate administrative functions 25 Reduce distribution and logistics expense 25 Savings ($ in millions) $100 Total synergies

  20. Slide 20: Enhance Margins

    Enhance Margins Increase mix of proprietary products Improve International and Healthcare margins Drive operating efficiency Fixed cost leverage Increasing profitability

  21. Slide 21: Increase Cash Flow: Reduced Investment in Working Capital

    1998 1999 2000 2001 2002 2003* 6 MOS 2004* East 0.131 0.112 0.093 0.091 0.086 0.077 0.074 As a Percentage of Sales Increase Cash Flow Reduced Investment in Working Capital * 2003 excludes impact of Perbio acqusition and 2004 excludes impact of Perbio, Oxoid and Dharmacon acquisitions. Note: Working

  22. Slide 22: Pursue Strategic Acquisitions

    Pursue Strategic Acquisitions Life science market Pharma services Other consolidation opportunities

  23. Slide 23: Strong Cash Flow Generation

    Strong Cash Flow Generation 2000 2001 2002 2003 2004F* 2005F* ($ in millions) 2000 2001 2002 2003 2004F 2005F East 1.75 2.24 1.99 2.27 2.57 3.16 Free Cash Flow per share *Midpoint of management estimates.

  24. Slide 24: Investment Highlights

    Investment Highlights Favorable market dynamics Powerful channel position Proven track record Significant upside opportunities Strong earnings and cash flow growth

  25. Slide 25: Questions and Answers

    Questions and Answers

  26. Slide 26: Supplementary Financial Information

    (in millions, except per share amounts) Supplementary Financial Information

Fisher Scientific International — Merger or Acquisition (August 2004) on 6ix